TG Therapeutics (NASDAQ: TGTX) shares surged Friday as unconfirmed takeover speculation propelled the biotech stock to its biggest single-session gain in months, with investors betting a major pharmaceutical company could be circling the multiple sclerosis drugmaker.

Market Context

The move comes amid broader biotech sector consolidation, where large-cap pharma companies have been actively pursuing bolt-on acquisitions to replenish pipelines facing patent cliffs. TGTX's meteoric rise Friday added roughly $1.5 billion in market capitalization at its intraday peak, with shares pulling back only slightly into the close as traders weighed the unverified nature of the takeover chatter against genuine fundamental strength.

Analysis

The catalyst was a report from Betaville suggesting a U.S. biopharma company with a market cap between $20 billion and $40 billion may be exploring a deal for TG Therapeutics. The report did not identify the potential buyer, and TGTX has not confirmed any takeover discussions are underway. This distinction is critical for traders: unconfirmed rumors can drive outsized moves in both directions, and gains built on speculation often prove ephemeral if negotiations never materialize or are publicly denied.

That said, the underlying business provides a legitimate case for strategic interest. TG Therapeutics' BRIUMVI has emerged as a genuine growth driver, with Q2 U.S. revenue hitting $227.7 million—up 64% year-over-year. The company subsequently raised its 2026 revenue guidance to approximately $950 million, suggesting management sees continued momentum in the multiple sclerosis market whereBRIUMVI competes against established players like Roche's Ocrevus.

Institutional investors have been building positions in TGTX ahead of potential catalysts, with the stock already up approximately 85% year-to-date entering Friday's session. The takeover premium now baked into the shares reflects Wall Street's appetite for biotech M&A, particularly for companies with commercial-stage drugs and clean intellectual property profiles.

Key Numbers

- Q2 U.S. BRIUMVI revenue: $227.7 million (+64% year-over-year)

- 2026 revenue guidance raised to approximately $950 million

- Year-to-date performance entering Friday: +85%

- Reported interested acquirer market cap range: $20 billion-$40 billion

What to Watch

Traders should monitor for any formal announcement from TG Therapeutics regarding strategic alternatives or takeover discussions. The company has not filed any 8-K with the Securities and Exchange Commission indicating ongoing negotiations, which is typical once a deal enters advanced stages. Any confirmation—or denial—from TGTX management will be the next major catalyst. Additionally, watch for unusual options activity as expiration approaches, as M&A rumors frequently concentrate put-call skews around rumored announcement dates.